Abstract 4304: Identification Of Risk Factors Related To Poor Angiogenic Potency Of Bone Marrow Cells From Different Patients
Background: Therapeutic angiogenesis induced by the implantation of autologous bone marrow-derived cells has been used for the treatment of ischemic diseases. However, as the outcomes of cell implantation obviously vary among patients, we must establish which patients benefit from this treatment.
Methods and Results: We collected clinical and laboratory data from 25 patients scheduled to undergo sternotomy for various surgical procedures. Then, we aspirated bone marrow cells from the sternum during the operation, and investigated their angiogenic potency in vitro by cultivation, and in vivo using an ischemic limb model in SCID mice. The angiogenic potency of bone marrow cells differed among patients. Univariate regression analysis identified 11 factors that significantly (P<0.10) impaired the improvement of blood flow in the ischemic limbs of SICD mice after the implantation of bone marrow cells from the patients. These included an age >65 years (r=0.518, P=0.008), anemia (hemoglobin<12 g/dl; r=0.467, P=0.018), renal failure, and increased serum levels of CRP, triglyceride, N-telopeptide of type I collagen, and IL-6, and others. However, diabetes, hypertension, and the serum levels of VEGF and PDGF did not significantly affect the blood flow of the ischemic limbs in the SCID mice implanted with the bone marrow cells from the patients. Furthermore, we assigned scores to these risk factors according to their P value. By calculating the total risk scores of each patient, we found that the total risk scores were very closely related to the blood flow of the ischemic limbs in SCID mice implanted with that patient’s bone marrow cells (r=−0.778, P<0.001). These risk scores can accurately predict the potency of their bone marrow cells for inducing therapeutic angiogenesis.
Conclusions: We identified the risk factors related to poor angiogenic potency of bone marrow cells and developed a new scoring system to predict their angiogenic potency for the treatment of ischemic diseases. Our results provide important information to help us select patients who may be more likely to benefit from this treatment in future clinical trials.